Previous 10 | Next 10 |
Pure play COVID-19 vaccine makers closed the 1H 2022 as some of the worst performers in the beaten-down biotech space amid concerns over how the group, once a pandemic favorite, could sustain growth as COVID impact wanes. The selloff, worse than the ~33% decline among biotech stocks...
The eleven sectors of the S&P 500 were 16.4% lower for Q2 2022, with SPDR S&P 500 Trust ETF closed more than 16% lower . The top five gainers in the health care sector (stocks with a market cap of over $2B) were: Turning Point Therapeutics ( TPTX ) +179.1...
NEW YORK, NY / ACCESSWIRE / June 30, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Zendesk, Inc. (NYSE:ZEN)'s sale to...
The deal is the downside. Antitrust suit could unlock value. Massive standalone upside. For further details see: Sanderson Farms Plays Chicken
How often can you say this? Never? Constantly? Rarely? Rational reactions to each. For further details see: 'The Market Is Wrong, I'm Right'
Time to put money to work. Merger arb spreads are wide. Here’s what you can buy today. For further details see: Biohaven Deal: Pfizer Gives Away A Freeroll
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray PR Newswire - Nurtec ODT open-label extensi...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society PR Newswire 31 new and encore presentations, inclu...
NEW YORK, NY / ACCESSWIRE / May 27, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Tivity Health, Inc. (NASDAQ:TVTY)'s ...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-24 06:30:09 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for BHVN on July 24, 2024 04:48AM ET. BHVN was trading at $37.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy reco...
2024-07-24 06:00:03 ET Terence Flynn from Morgan Stanley issued a price target of $58.00 for BHVN on 2024-07-24 04:48:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $37.81. The overall price target consensus is at $4...
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...